HIV-1 Reservoir Persistence and Decay: Implications for Cure Strategies

Curr HIV/AIDS Rep. 2022 Jun;19(3):194-206. doi: 10.1007/s11904-022-00604-2. Epub 2022 Apr 11.

Abstract

Purpose of review: Despite suppressive antiretroviral therapy (ART), a viral reservoir persists in individuals living with HIV that can reignite systemic replication should treatment be interrupted. Understanding how HIV-1 persists through effective ART is essential to develop cure strategies to induce ART-free virus remission.

Recent findings: The HIV-1 reservoir resides in a pool of CD4-expressing cells as a range of viral species, a subset of which is genetically intact. Recent studies suggest that the reservoir on ART is highly dynamic, with expansion and contraction of virus-infected cells over time. Overall, the intact proviral reservoir declines faster than defective viruses, suggesting enhanced immune clearance or cellular turnover. Upon treatment interruption, rebound viruses demonstrate escape from adaptive and innate immune responses, implicating these selective pressures in restriction of virus reactivation. Cure strategies employing immunotherapy are poised to test whether host immune pressure can be augmented to enhance reservoir suppression or clearance. Alternatively, genomic engineering approaches are being applied to directly eliminate intact viruses and shrink the replication-competent virus pool. New evidence suggests host immunity exerts selective pressure on reservoir viruses and clears HIV-1 infected cells over years on ART. Efforts to build on the detectable, but insufficient, reservoir clearance via empiric testing in clinical trials will inform our understanding of mechanisms of viral persistence and the direction of future cure strategies.

Keywords: Cure; HIV-1 reservoirs; Persistence; Viral rebound.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-Retroviral Agents / therapeutic use
  • CD4-Positive T-Lymphocytes
  • HIV Infections*
  • HIV Seropositivity* / drug therapy
  • HIV-1*
  • Humans
  • Proviruses / genetics
  • Viral Load
  • Virus Latency
  • Virus Replication

Substances

  • Anti-Retroviral Agents